MedPath

Impact of Hepatectomy on HCC Recurrence

Completed
Conditions
Recurrence
Hepatocellular Carcinoma Stage I
Interventions
Procedure: Major hepatectomy
Registration Number
NCT06390228
Lead Sponsor
Anhui Medical University
Brief Summary

Hepatectomy is the first option for the treatment of hepatocellular carcinoma(HCC) at CNLC Ib stage. HCC patients who undergo curative hepatectomy may experience varying remnant liver volumes and thus leads to different oncological outcomes.

Detailed Description

Patients with hepatocellular carcinoma (HCC) who undergo curative hepatectomy may experience varying remnant liver volumes. The investigators aimed to evaluate whether the extent of liver resection has an effect on postoperative recurrence in HCC patients. A retrospective analysis was conducted on 197 patients who underwent hepatectomy for a solitary HCC lesion measuring ≥5 cm between January 2019 and June 2022. Patients were divided into major hepatectomy (MAH) group (n=70) and minor hepatectomy (MIH) group (n=127) based on the extent of liver resection. Recurrence-free survival (RFS) was compared between the two groups. Propensity score matching was employed to mitigate potential biases in this research.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
197
Inclusion Criteria
  • histologically confirmed solitary HCC with a size of ≥5 cm
  • Eastern Cooperative Oncology Group score of 0 or 1
  • preoperative indocyanine green retention rate at 15 minutes ≤15% and Child-Pugh A classification
  • no evidence of vascular invasion or extrahepatic disease.
Exclusion Criteria
  • not diagnosed with HCC or had an HCC measuring <5 cm
  • had confirmed tumor metastases or macrovascular invasion based on radiological examinations
  • died within 90 days after surgery were excluded

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
Major hepatectomyMajor hepatectomyMajor hepatectomy was defined as the removal of four or more Couinaud's liver segments.
Primary Outcome Measures
NameTimeMethod
recurrence-free survival2019.1-2023.8

the time from the time of radical surgery to the time of HCC recurrence

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Anhui Provincial Hospital

🇨🇳

Hefei, Anhui, China

© Copyright 2025. All Rights Reserved by MedPath